MHC class II HER-2/neu antigen vaccine (Marker Therapeutics)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameMHC class II HER-2/neu antigen vaccine (Marker Therapeutics)

Drug Alias NameMHC class II HER-2/neu antigen vaccine (Mayo)MHC class II HER-2/neu antigen vaccine (TapImmune)MHC class II HER-2/neu antigen vaccine (Mayo/TapImmune)

ClassificationBiologics > Protein drugs > Recombinant polypeptideVaccines > Development/production technology > Inactivated vaccine > Subunit vaccineVaccines > Application > Therapeutic vaccine +[4]

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulators

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesMayo Clinic

China Registration ClassN/A

Develop Information

Active CompaniesMarker Therapeutics Inc

Inactive CompaniesMayo Clinic

Active IndicationsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A